Revance Therapeutics Inc (NASDAQ: RVNC) is -64.96% lower on its value in year-to-date trading and has touched a low of $2.30 and a high of $9.74 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RVNC stock was last observed hovering at around $3.08 in the last trading session, with the day’s loss setting it 0.0%.
Currently trading at $3.08, the stock is -7.86% and -27.38% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.7 million and changing 0.00% at the moment leaves the stock -28.68% off its SMA200. RVNC registered -65.12% loss for a year compared to 6-month gain of 19.38%. The firm has a 50-day simple moving average (SMA 50) of $4.2839 and a 200-day simple moving average (SMA200) of $4.3347.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -18.95% loss in the last 1 month and extending the period to 3 months gives it a -42.86%, and is 0.33% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 0.56% over the week and 3.59% over the month.
Revance Therapeutics Inc (RVNC) has around 597 employees, a market worth around $321.52M and $247.00M in sales. Profit margin for the company is -74.67%. Distance from 52-week low is 33.91% and -68.39% from its 52-week high. The company has generated returns on investments over the last 12 months (-62.94%).
The EPS is expected to grow by 42.40% this year
270.0 institutions hold shares in Revance Therapeutics Inc (RVNC), with institutional investors hold 90.65% of the company’s shares. The shares outstanding are 104.90M, and float is at 95.30M with Short Float at 10.26%. Institutions hold 82.89% of the Float.
The top institutional shareholder in the company is CAPITAL WORLD INVESTORS with over 13.94 million shares valued at $35.82 million. The investor’s holdings represent 15.164 of the RVNC Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 8.57 million shares valued at $22.01 million to account for 9.3183 of the shares outstanding. The other top investors are FRANKLIN RESOURCES INC which holds 6.26 million shares representing 6.8092 and valued at over $16.09 million, while VANGUARD GROUP INC holds 6.5215 of the shares totaling 5.99 million with a market value of $15.41 million.
Revance Therapeutics Inc (RVNC) Insider Activity
The most recent transaction is an insider sale by Hollander David, the company’s CMO & Global Therapeutics Lead. SEC filings show that Hollander David sold 3,908 shares of the company’s common stock on Nov 18 ’24 at a price of $4.17 per share for a total of $16296.0. Following the sale, the insider now owns 0.1 million shares.
Revance Therapeutics Inc disclosed in a document filed with the SEC on Apr 16 ’24 that Jordan Erica (Chief Commercial Officer) sold a total of 2,392 shares of the company’s common stock. The trade occurred on Apr 16 ’24 and was made at $3.80 per share for $9096.0. Following the transaction, the insider now directly holds 0.11 million shares of the RVNC stock.
Still, SEC filings show that on Mar 18 ’24, Sjuts Dustin S (President) disposed off 9,211 shares at an average price of $5.04 for $46446.0. The insider now directly holds 167,550 shares of Revance Therapeutics Inc (RVNC).
